July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Regulation of the Keratoconic in vitro phenotype through Integrated stress response stimulation
Author Affiliations & Notes
  • James William Foster
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Uri Soiberman
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Michelle Lu
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Ahmed Shehata
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Tempest Young
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Yassine Daoud
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Albert S Jun
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   James Foster, None; Uri Soiberman, None; Michelle Lu, None; Ahmed Shehata, None; Tempest Young, None; Yassine Daoud, None; Albert Jun, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James William Foster, Uri Soiberman, Michelle Lu, Ahmed Shehata, Tempest Young, Yassine Daoud, Albert S Jun; Regulation of the Keratoconic in vitro phenotype through Integrated stress response stimulation. Invest. Ophthalmol. Vis. Sci. 2019;60(9):328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We have recently identified activation of the integrated stress response (ISR) in keratoconic corneas and in vitro fibroblast cultures. We sought to investigate the effect of modulating the activation state of normal and keratoconic fibroblasts in an effort to recapitulate the diseased phenotype in healthy cells and further probe the nature of this activation.

Methods : Donor corneal fibroblasts (DN) were extracted from limbal rings and corneal buttons and expanded in serum containing media. These were then treated with tunicamycin (0.1-1μg/ml) or the cell-permeable eIF-2a phosphatase inhibitor SAL003 (10-0.5μM). Cell survival, was monitored by resazurin reduction. MMP production was monitored with Gelatin zymography and Collagen production was measured via hydroxyproline and sirius red incorporation. qPCR, immunohistochemistry and Western Blotting was used to measure ATF4 activity and ISR status.

Results : Activation of the ISR (SAL003/Tunicamycin) did not cause profound cell loss over 7 dayas in culture. However, we observed increase in MMP2 production (n=4) in response to tunicamycin (7.4±0.8) and SAL003 (4.7±0.4), when normalized to final cell number. We also observe a dose dependent decrease in collagen production over 7 days by both sirius red and hydroxyproline production with an Ic50 of 5µM (n=5) for SAL003. We observe increases in the production of CRP55 and CTAGE5 in treated cells as we have previously published for keratoconic fibroblasts. We have also correlated this with PERK phosphorylation in ex vivo keratoconic corneas and in vitro keratoconic fibroblasts.

Conclusions : Our results demonstrate that the activation of the ISR in healthy fibroblasts recapitulates critical aspects of the observed in vitro keratoconic fibroblast phenotype. We have demosntrated that triggering an unfolded protein response, simialr to that observed ex vivo triggers an increase in catabolic enzymes, decrease in collagen production and eventual cell death. We believe that targetting the integrated stress reponse represents a novel therapeutic opportunity for keratoconus.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×